Figure 5.

Mean changes from baseline Functional Assessment of Cancer Therapy Kidney Symptom Index–Disease-Related Symptoms (FKSI-DRS) scores.

^aMean change from baseline was also clinically meaningful at weeks 144, 164, and 176 in the nivolumab arm.

^bN=8 for week 232 and n<10 after week 236 in the nivolumab arm; N=9 for weeks 124, 128, and 136 in the everolimus arm, and n<10 otherwise after week 132.

*Denotes clinically meaningful improvement with nivolumab (+2) or deterioration with EVE (–2) from baseline (dashed lines).

Only time points for which data were available for ≥10 randomized patients with baseline plus ≥1 postbaseline HRQoL assessment with non-missing patient-reported outcome data per arm were included.

Time 0 indicates baseline.

Bars show 95% confidence intervals.